Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Inovio: INO-4800 DNA Vaccine Against the Novel Coronavirus Has Promising News. Moderna Still Has the Front-Runner

May 20, 2020 0

Inovio DNA Vaccine Candidate INO-4800 for SARS-CoV-2 Inovio (INO) announced the publication of the preclinical study …

Moderna: Pricing of a Public Offering of 17,600,000 Shares at $76.00 Per Share

May 19, 2020 0

Moderna Inc: A Public Offering Moderna (MRNA) announced the pricing of an underwritten public offering of …

Moderna: Positive Interim Phase 1 Data for its mRNA-1273 Vaccine Against Novel Coronavirus

May 18, 2020 0

Moderna Postive News for mRNA-1273 Vaccine Against Novel Coronavirus (COVID-19) Moderna (MRNA) announced positive interim clinical …

Sorrento Therapeutics: STI-1499 ~ An Encouraging Anti-SARS-CoV-2 Antibody

May 16, 2020 0

Sorrento Therapeutics Anti-SARS-CoV-2 Antibody STI-1499 Sorrento Therapeutics (SRNE) announced that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% …

Bristol-Myers Squibb and bluebird bio Product Ide-Cel, Bb2121 and the FDA Refusal Letter. What Do We Expect?

May 13, 2020 0

Bristol-Myers Squibb and bluebird bio Bristol-Myers Squibb (BMY) and bluebird bio (

Novavax: A Profile and a Comment. See Also: Why We Need More Firms to Develop Coronavirus Vaccines

May 13, 2020 0

Novavax Still Rallying After Grant The Grant That Continues To Rally the Stock Novavax (NVAX) stock …

The Impacting News of the Day

May 12, 2020 0

Impacting News from Novavax, CymaBay Therapeutics and Sanofi SA Novavax The Grant That Rallied the Stock …

Novel Coronavirus: The Therapeutics

May 11, 2020 0

Prohost Letter #440 Coronavirus The Therapeutics Gilead’s Remdesivir Treating COVID-19 patients requires therapeutic products that can …

Pluristem Therapeutics: The FDA Cleared Phase 2 Study of Its PLX Cells in Treating the Respiratory Complications of COVID-19

May 8, 2020 0

Pluristem Therapeutics IND Cleared by FDA for PLX Cells in COVID-19 Treatment From Pluristem Therapeutics (PSTI) …

The FDA Cleared Moderna’s Coronavirus Vaccine for a Phase 2 Trial. The Stock Surged in Pre-market Hours

May 7, 2020 0

Moderna Coronavirus Vaccine Cleared for Phase 2 Moderna (MRNA) provided business updates for the first quarter of …

Alexion Pharmaceuticals to Acquire Portola at $18 Per Share

May 5, 2020 0

Alexion to Acquire Portola Alexion (ALXN) and Portola (PTLA) entered into a definitive merger agreement and …

Applied DNA Sciences and Takis Biotech: A DNA Vaccination Injection in Animals Induced Antibodies That Block SARS-CoV-2

May 4, 2020 0

Applied DNA Sciences and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA …

The Time Has Come for This Small Biotech Firm to Grow and Thrive

April 30, 2020 0

CytomX Therapeutics CytomX (CTMX) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational …

Moderna: Speeding down the Road Towards Developing a Prophylactic Vaccine Against the Novel Coronavirus (SARS-CoV-2)

April 28, 2020 0

Moderna Submitted an IND for Its mRNA Vaccine Candidate for Novel Coronavirus Moderna (MRNA) announced that …

Sanofi and Regeneron: Remarkable Results from Libtayo’s Trial on Patients with Advanced Non-Small Cell Lung Cancer

April 27, 2020 0

Sanofi and Regeneron: Results from Libtayo® Trial Sanofi (SNY) and Regeneron (REGN)

Be Careful NOT to Underestimate the Following Biotech Stocks (Part 2)

April 26, 2020 0

Theravance Biopharma: Near-Term Game-Changing PDUFAS Some of the Prohost Portfolio selected companies are having near term …

Be Careful NOT to Underestimate the Following Biotech Stocks (Part 1)

April 24, 2020 0

Halozyme and PTC Therapeutics: Near-Term Game-Changing PDUFAS Some of the Prohost Portfolio selected companies are having …

Compugen: A New Important Patent from Europe and Much More

April 22, 2020 0

Compugen: In the NEWS Compugen (CGEN) was granted a new patent for the composition of COM701 …

The World Focus is on COVID-19 Treatments and Vaccines

April 20, 2020 0

The Week in Review #50 The World FOCUS is COVID-19 The world FOCUS right now is …

Exelixis is Rallying Today from CheckMate-9ER Trial Results

April 20, 2020 0

Exelixis Rallying from CheckMate-9ER Trial Results Exelixis (EXEL) and Bristol-Myers Squibb (

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Inovio: INO-4800 DNA Vaccine Against the Novel Coronavirus Has Promising News. Moderna Still Has the Front-Runner

Moderna: Pricing of a Public Offering of 17,600,000 Shares at $76.00 Per Share

Moderna: Positive Interim Phase 1 Data for its mRNA-1273 Vaccine Against Novel Coronavirus

Sorrento Therapeutics: STI-1499 ~ An Encouraging Anti-SARS-CoV-2 Antibody

Bristol-Myers Squibb and bluebird bio Product Ide-Cel, Bb2121 and the FDA Refusal Letter. What Do We Expect?

Novavax: A Profile and a Comment. See Also: Why We Need More Firms to Develop Coronavirus Vaccines

The Impacting News of the Day

Novel Coronavirus: The Therapeutics

Pluristem Therapeutics: The FDA Cleared Phase 2 Study of Its PLX Cells in Treating the Respiratory Complications of COVID-19

The FDA Cleared Moderna’s Coronavirus Vaccine for a Phase 2 Trial. The Stock Surged in Pre-market Hours

Alexion Pharmaceuticals to Acquire Portola at $18 Per Share

Applied DNA Sciences and Takis Biotech: A DNA Vaccination Injection in Animals Induced Antibodies That Block SARS-CoV-2

The Time Has Come for This Small Biotech Firm to Grow and Thrive

Moderna: Speeding down the Road Towards Developing a Prophylactic Vaccine Against the Novel Coronavirus (SARS-CoV-2)

Sanofi and Regeneron: Remarkable Results from Libtayo’s Trial on Patients with Advanced Non-Small Cell Lung Cancer

Be Careful NOT to Underestimate the Following Biotech Stocks (Part 2)

Be Careful NOT to Underestimate the Following Biotech Stocks (Part 1)

Compugen: A New Important Patent from Europe and Much More

The World Focus is on COVID-19 Treatments and Vaccines

Exelixis is Rallying Today from CheckMate-9ER Trial Results